We’ve downgraded MDS

Article Excerpt

MDS INC. $7.83 (Toronto symbol MDS; Aggressive Growth Portfolio, Consumer sector; Shares outstanding: 120.1 million; Market cap: $940.4 million; Price-to-sales ratio: 0.7; No dividends paid since October 2006; SI Rating: Extra Risk) has three businesses: MDS Analytical Technologies sells mass spectrometers that detect and measure substances in blood and other patient samples; MDS Pharma Services conducts contract-drug research for pharmaceutical companies; and MDS Nordion supplies medical isotopes for cancer research. The company recently agreed to sell its Analytical Technologies business for $650 million (all amounts except share price and market cap in U.S. dollars). U.S. anti-trust regulators are still examining the deal, but it should close in early 2010. MDS will use $400 million to $450 million of these funds to buy back shares. It will probably put the remaining proceeds toward its $245-million long-term debt, which is about a quarter of its market cap. MDS also holds cash of $298 million, or $2.48 a share. The company also wants to sell its…